aTYR PHARMA INC
ATYR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001339970
No open-market purchases or sales by aTYR PHARMA INC insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $24.2M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −20 vs. previous quarter
- 89
- 13F valueReported value at the end of Q2 2026
- $24.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ATYR, Q2 2026
No superinvestor reported holding ATYR at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by aTYR PHARMA INC insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 28, 2026 (view filing) | May 27 | 1 day | Schimmel PaulDirector | PPurchase | +100.0K | $0.50 | +$50.0K | +14.7%779.1K after | |
| Feb 4, 2026 (view filing) | Feb 4 | Same day | Shukla SanjayPresident and CEO | SSale | −3.75K | $0.98 | −$3.67K | −2.4%153.6K after | |
| Feb 4, 2026 (view filing) | Feb 4 | Same day | Broadfoot Jill MarieChief Financial Officer | SSale | −1.56K | $0.98 | −$1.53K | −4.0%37.3K after | |
| Feb 4, 2026 (view filing) | Feb 4 | Same day | Denyes NancyGeneral Counsel | SSale | −1.12K | $0.98 | −$1.10K | −3.3%33.1K after | |
| Oct 9, 2025 (view filing) | Oct 8-9 | 1 day | Schimmel PaulDirector | PPurchase | +1.00M | $0.9127 | +$912.7K | +242.1%1.41M after | 2 lots |
| Mar 17, 2025 (view filing) | Mar 17 | Same day | Gross Jane ADirector | PPurchase | +3.75K | $4.00 | +$15.0K | +62.5%9.75K after | |
| Feb 4, 2025 (view filing) | Feb 4 | Same day | Broadfoot Jill MarieChief Financial Officer | SSale | −1.25K | $3.78 | −$4.74K | −3.8%31.8K after | |
| Feb 4, 2025 (view filing) | Feb 4 | Same day | Denyes NancyGeneral Counsel | SSale | −899 | $3.78 | −$3.40K | −3.3%26.6K after | |
| Jul 24, 2024 (view filing) | Jul 22-24 | 2 days | Schimmel PaulDirector | PPurchase | +100.0K | $1.84 | +$184.5K | +31.9%413.0K after | 3 lots |
| Jun 6, 2024 (view filing) | Jun 5 | 1 day | Denyes NancyGeneral Counsel | PPurchase | +5.00K | $1.86 | +$9.30K | +29.0%22.3K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in aTYR PHARMA INC at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 8,509,678 | $5.08M | 0.01% | −2,000,000−19.0% | Reduced |
| Vanguard Capital Management LLC | 3,808,091 | $2.27M | 0.00% | −4,041−0.1% | Reduced |
| Kalehua Capital Management LLC | 3,576,334 | $2.13M | 0.68% | +3,576,334 | New |
| Gsa Capital Partners LLP | 3,454,863 | $2.06M | 0.13% | +1,770,277+105.1% | Added |
| AQR Capital Management LLC | 2,610,548 | $1.56M | 0.00% | +2,114,530+426.3% | Added |
| FMR LLC | 2,471,418 | $1.47M | 0.00% | −12,235,425−83.2% | Reduced |
| BlackRock, Inc. | 1,827,332 | $1.09M | 0.00% | −4,616,572−71.6% | Reduced |
| Jane Street Group, LLC | 1,721,297 | $1.03M | 0.00% | +1,672,795+3,448.9% | Added |
| UBS Group AG | 1,531,151 | $914.1K | 0.00% | −2,336,062−60.4% | Reduced |
| Morgan Stanley | 1,343,636 | $801.9K | 0.00% | +118,169+9.6% | Added |